Generic Tasigna

Common Use

Tasigna is used to treat chronic myeloid leukemia (CML) in patients who are Philadelphia chromosome-positive. It works by blocking specific proteins (tyrosine kinases) that promote cancer cell growth.

Dosage and Direction

Take Tasigna exactly as prescribed, usually twice a day on an empty stomach. Swallow the capsules whole with water, at least two hours after eating and avoid food for at least one hour after taking the dose.

Precautions

Regular monitoring of heart rhythm, liver function, and blood counts is essential during treatment. Inform your doctor if you have heart conditions, low magnesium or potassium levels, or liver disease.

Contraindications

Do not use Tasigna if you have a known hypersensitivity to nilotinib. It is contraindicated in patients with long QT syndrome or those taking drugs known to prolong the QT interval.

Possible Side Effect

Common side effects include rash, headache, nausea, and fatigue. Serious risks involve heart rhythm disturbances (QT prolongation), liver toxicity, and low blood cell counts.

Drug Interaction

Avoid using Tasigna with strong CYP3A4 inhibitors or inducers, as they may alter drug levels. Grapefruit products should also be avoided due to interaction risks.

Missed Dose

If you miss a dose, skip it and take the next dose at the scheduled time. Do not double up or take extra doses to compensate.

Overdose

Overdose symptoms may include severe nausea, vomiting, and abnormal heart rhythms. Immediate medical attention is required in such cases.

Storage

Store at room temperature in a dry place away from heat and direct light. Keep the medication in its original container and out of reach of children.

Disclaimer

We provide only general information about medications which does not cover all directions, possible drug integrations, or precautions. Information at the site cannot be used for self-treatment and self-diagnosis. Any specific instructions for a particular patient should be agreed with your health care adviser or doctor in charge of the case. We disclaim reliability of this information and mistakes it could contain. We are not responsible for any direct, indirect, special or other indirect damage as a result of any use of the information on this site and also for consequences of self-treatment.

Clinical Verification

Last Clinically Updated: August 15, 2026

Written By

Dr. Elena Vance, PharmD

Clinical Specialist in Neuropharmacology

Fact Checked By

Marcus Thorne, MS

Biomedical Data & FDA Label Verification

Medically Reviewed By

Dr. Arthur Campbell, MD

Board-Certified Psychiatrist (ABPN)